Trial Profile
Hematopoietic Stem Cell Transplant for Sickle Cell Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Fludarabine (Primary) ; Antithymocyte globulin; Cyclophosphamide; Haematopoietic stem cell therapy; Methotrexate; Mycophenolate mofetil; Tacrolimus
- Indications Sickle cell anaemia; Thalassaemia
- Focus Therapeutic Use
- 17 Feb 2023 Status changed from active, no longer recruiting to completed.
- 06 Feb 2023 Planned End Date changed from 1 Jun 2023 to 31 Dec 2029.
- 06 Feb 2023 Planned primary completion date changed from 1 Dec 2022 to 31 Dec 2026.